We
herein report the conventional and microscale parallel synthesis
of selective inhibitors of human blood coagulation factor XIIa and
thrombin exhibiting a 1,2,4-triazol-5-amine scaffold. Structural variations
of this scaffold allowed identifying derivative 21i,
a potent 29 nM inhibitor of FXIIa, with improved selectivity over
other tested serine proteases and also finding compound 21m with 27 nM inhibitory activity toward thrombin. For the first time,
acylated 1,2,4-triazol-5-amines were proved to have anticoagulant
properties and the ability to affect thrombin- and cancer-cell-induced
platelet aggregation. Performed mass spectrometric analysis and molecular
modeling allowed us to discover previously unknown interactions between
the synthesized inhibitors and the active site of FXIIa, which uncovered
the mechanistic details of FXIIa inhibition. Synthesized compounds
represent a promising starting point for the development of novel
antithrombotic drugs or chemical tools for studying the role of FXIIa
and thrombin in physiological and pathological processes.
Herein we report a microscale parallel synthetic approach allowing for rapid access to libraries of N‐acylated aminotriazoles and screening of their inhibitory activity against factor XIIa (FXIIa) and thrombin, which are targets for antithrombotic drugs. This approach, in combination with post‐screening structure optimization, yielded a potent 7 nM inhibitor of FXIIa and a 25 nM thrombin inhibitor; both compounds showed no inhibition of the other tested serine proteases. Selected N‐acylated aminotriazoles exhibited anticoagulant properties in vitro influencing the intrinsic blood coagulation pathway, but not extrinsic coagulation. Mechanistic studies of FXIIa inhibition suggested that synthesized N‐acylated aminotriazoles are covalent inhibitors of FXIIa. These synthesized compounds may serve as a promising starting point for the development of novel antithrombotic drugs.
A fast
and fully automated method for chiral analysis has been
developed by combining a chiral derivatization approach with high-resolution
trapped ion mobility separation. Although the presented approach can
be potentially applied to diverse types of chiral compounds, several
benchmark amino acids were used as model compounds, focusing on the
smallest amino acid alanine. An autosampler with an integrated chromatography
system was used for inline chiral derivatization with (S)-naproxen chloride and subsequent preseparation. Afterwards, derivatized
amino acids were directly introduced into the electrospray interface
of a trapped ion mobility–mass spectrometer for rapid diastereomer
separation in the gas phase. This unique combination of preseparation
and trapped ion mobility spectrometry separation in the negative ion
mode enabled rapid chiral analysis within 3 min per sample. Furthermore,
the diastereomer separation proved to be independent of alkali salts
or other metal ions, offering robustness with regard to samples containing
high amounts of salts. Highly sensitive detection of amino acid diastereomers
was possible down to the lower nanomolar concentration range, and
enantiomeric ratios could be readily determined from the recorded
mobilograms with excellent reproducibility and precision. To demonstrate
the general applicability of our method, alanine and other amino acids
were analyzed from soy sauces and seasonings, which revealed extraordinarily
high d-Ala contents of up to 99% in all samples.
In this study, the combination of speciation analysis and native mass spectrometry is presented as a powerful tool to gain new insight into the diverse interactions of environmentally relevant organotin...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.